Lund, Sweden, January 20, 2021– Alligator Bioscience (Nasdaq Stockholm: ATORX) Alligator Bioscience (Nasdaq Stockholm: ATORX), announces today that the composition of the Nomination Committee prior to the Annual General Meeting on May 5, 2022 has changed as a result of a change of ownership.
The composition of the Nomination Committee prior to the 2022 Annual General Meeting was announced in a press release on November 3, 2021. Allegro Investment, Inc. has since December 2021 acquired shares corresponding to approximately 22.2 percent of the total number of shares and votes in the company and thereby become the largest shareholder in Alligator Bioscience. AB. As a result of the change of ownership, the composition of the Nomination Committee, in accordance with the instructions for the Nomination Committee adopted by the Annual General Meeting, has changed by Claus Asbjørn Andersson (representing Sunstone Life Science Ventures II K / S) leaving the Nomination Committee and Jan Lundström (representing Allegro Investment, Inc.) entered as a new member of the Nomination Committee.
Following the change, the Nomination Committee for the 2022 Annual General Meeting consists of the following persons:
– Jan Lundström, representing Allegro Investment Fund, L.P.;
– Lars Bergkvist, representing Jonas Sjögren;
– Hans-Peter Ostler, representing Lars Spånberg; and
– Anders Ekblom, Chairman of the Board.
Lars Bergkvist remains as chairman of the nomination committee.
"In connection with Jan Lundström becoming a new member of the Nomination Committee, I would like to take this opportunity to welcome Allegro Investment, Inc. as a stable, long-term and significant owner of Alligator Bioscience," says Anders Ekblom, Chairman of the Board of Alligator Bioscience AB.
The Nomination Committee's task is to prepare and present proposals to the Annual General Meeting before the Annual General Meeting, number of Board members elected by the Annual General Meeting, Chairman and other Board members elected by the Board, fees and other remuneration to each of the Board members elected and to Board members. , fees to the auditor and election of the nomination committee or decision on principles for the appointment of the nomination committee and decision on instructions for the nomination committee.
Shareholders who wish to submit comments or submit proposals to the Nomination Committee can do so via e-mail marked “Att. Nomination Committee” to info@alligatorbioscience.com or via letter to Alligator Bioscience AB, Nomination Committee, Medicon Village, 223 81 Lund. In order for the Nomination Committee to be able to consider a proposal, the proposal must have been received in good time before the Annual General Meeting, but no later than 31 January 2022.
The Nomination Committee's proposal will be presented in the notice convening the Annual General Meeting and on the company's website.
For further information:
Julie Silber, Director Investor Relations & Communications
Phone +: +46 46-540 82 23
E-mail: jur@alligatorbioscience.com
The information was submitted for publication, through the agency of the contact person set out above, at 8:00 a.m. CET on January 20, 2022.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc. and several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, with MacroGenics Inc. and its RUBY™ bispecific platform with Orion Corporation. Out licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden. For more information, please visit http://www.alligatorbioscience.com.